$1.96+0.19 (+10.73%)
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.
Compass Therapeutics, Inc. in the Healthcare sector is trading at $1.96. The stock is currently near its 52-week low of $1.61, remaining 57.5% below its 200-day moving average. Technical signals show oversold RSI of 26 and bearish MACD signal, explaining why CMPX maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bisp...
Compass Therapeutics recently reported that its Phase 2/3 COMPANION-002 trial in previously treated advanced biliary tract cancer met the primary endpoint, with tovecimig plus paclitaxel achieving higher response rates and longer median progression-free survival than paclitaxel alone, while maintaining a safety profile consistent with earlier studies. An interesting insight from the data is that patients who crossed over from paclitaxel alone to the tovecimig combination, despite initially...
Micron initiated, Rambus downgraded: Wall Street's top analyst calls
Compass Therapeutics will still submit tovecimig for approval despite the OS miss.
The major averages were broadly lower amid stalled peace negotiations between the U.S. and Iran as well as new escalation in the Strait of Hormuz. Investors are also balancing continued strength in corporate earnings and AI-driven optimism with rising geopolitical tension and macro uncertainty. Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart I
Compass Therapeutics (NASDAQ:CMPX) executives highlighted what CEO and Vice Chair Dr. Thomas Schuetz called “absolutely stunning” progression-free survival results from the company’s phase II/III COMPANION-002 trial in second-line advanced biliary tract cancer, while also detailing how patient cross